Improving Breviscapine Oral Bioavailability by Preparing Nanosuspensions, Liposomes and Phospholipid Complexes

Zilin Song,Jiaojiao Yin,Peifu Xiao,Jin Chen,Jingxin Gou,Yanjiao Wang,Yu Zhang,Tian Yin,Xing Tang,Haibing He
DOI: https://doi.org/10.3390/pharmaceutics13020132
IF: 6.525
2021-01-20
Pharmaceutics
Abstract:Breviscapine (BVP), a flavonoid compound, is widely used in the treatment of cardiovascular and cerebrovascular diseases; however, the low oral bioavailability and short half-life properties limit its application. The aim of this study was to investigate the three preparations for improving its oral bioavailability: nanosuspensions (BVP-NS), liposomes (BVP-LP) and phospholipid complexes (BVP-PLC). In vitro and in vivo results suggested that these three could all significantly improved the cumulative released amount and oral bioavailability compared with physical mixture, in which BVP-PLC was the most optimal preparation with the relative bioavailability and mean retention time of 10.79 ± 0.25 (p < 0.01) and 471.32% (p < 0.01), respectively. Furthermore, the influence of drug-lipid ratios on the in vitro release and pharmacokinetic behavior of BVP-PLC was also studied and the results showed that 1:2 drug-lipid ratio was the most satisfactory one attributed to the moderate-intensity interaction between drug and phospholipid which could balance the drug loading and drug release very well.
pharmacology & pharmacy
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to improve the oral bioavailability of Breviscapine (abbreviated as BVP). BVP is a flavonoid compound extracted from the traditional Chinese medicine Lobelia sessilifolia, and is widely used in the treatment of cardiovascular and cerebrovascular diseases. However, due to its low oral bioavailability and short half - life, its application range is limited. This article studied the methods of improving the oral bioavailability of BVP by preparing three preparations: nano - suspension (BVP - NS), liposome (BVP - LP) and phospholipid complex (BVP - PLC). The research results show that all three preparations can significantly increase the cumulative release amount and oral bioavailability of BVP, among which BVP - PLC performs the best, with a relative bioavailability of 10.79 ± 0.25 (p < 0.01) and an average residence time of 471.32% (p < 0.01). In addition, the influence of the drug - lipid ratio on the in - vitro release and pharmacokinetic behavior of BVP - PLC was also studied. The results show that the drug - lipid ratio of 1:2 is the most ideal, because the interaction strength between the drug and phospholipid at this ratio is moderate, which can well balance the drug loading and drug release.